featured
Ibrutinib Plus Lenalidomide and Rituximab Treats Relapsed or Refractory DLBCL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ibrutinib Plus Lenalidomide and Rituximab Has Promising Activity in Relapsed/Refractory Non-Germinal Center B-Cell-Like DLBCL
Blood 2019 Sep 26;134(13)1024-1036, A Goy, R Ramchandren, N Ghosh, J Munoz, DS Morgan, NH Dang, M Knapp, M Delioukina, E Kingsley, J Ping, DM Beaupre, JK Neuenburg, J RuanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.